The recommendation, backed by CDC director Mandy Cohen, affects approved pneumococcal vaccines such as MSD (Merck & Co)’s Capvaxive and Pfizer’s Prevnar 20. Currently, the CDC recommends pneumococcal vaccination for adults aged 65 years and older, as well as in young Adults aged 19 to 65 with certain risk conditions.
Prevnar 20 (20-valent pneumococcal conjugate vaccine/PCV20) was approved by the US Food and Drug Administration (FDA) for adults over 18 years of age in 2021. Two years later, the agency expanded the vaccine label to include infants and children, From 6 weeks old to 17 years old. Prevnar generated $6.4 billion in sales last year, according to Pfizer’s financials. GlobalData expects the vaccine to continue to generate comparable sales of $6.3 billion in 2030.
GlobalData is the parent company of Pharmaceutical Technology.
ADCOM’s recommendations are non-binding and become official only after they are reviewed and finalized by the Director of CDC and the Director of the Department of Health and Human Services.
“US CDC Adcom recommends lowering the age of pneumococcal vaccines” was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, regardless of whether express or implied as to its accuracy or completeness. We do not give any representations, warranties or warranties. You should obtain professional or specialist advice before taking or refraining from taking any action based on the content of our site.
